UNSPSC 51401522: Ethyl dirazepate

This classification denotes a benzodiazepine with the molecular formula C18H14Cl2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 74FAA305EW, chemically known as ethyl 7-chloro-5-(o-chlorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepine-3-carboxylate. but generally known as ethyl dirazepate, which bears US NIH Compound Identifier 208941. European Medicines Agency schedules Ethyl dirazepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07289MIG.

UNSPSC 51401522 Ethyl dirazepate is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including naloxone, generic multi-source drugs, and over-the-counter medications supplied through authorized wholesalers and direct distribution channels. State and local governments under this code are sourcing emergency response medications, community health supplies, and prescription inventory to support public health initiatives, corrections facilities, and employee health plans. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The mix reflects both direct purchase solicitations from individual counties and statewide or regional cooperative frameworks that establish master agreements for multiple government entities to draw from.

Recent activity spans three distinct procurement approaches across Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, responses due July 26, 2023 (note: the due date appears anomalous in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit managers. Most significantly, the Minnesota Department of Administration's Office of State Procurement, administering the Multistate Cooperative Purchasing Alliance (MMCAP), released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, structured to serve participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions through three authorized wholesalers. The MMCAP opportunity emphasizes NDC-level product specification, cGMP and DSCSA compliance, competitive pricing models, and performance standards with penalties for non-compliance.